Addex Therapeutics (CH:ADXN)
:ADXN
Want to see CH:ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
CHF0.05
<CHF0.01(4.55%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.03 - CHF0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)206.07K
Market Cap
CHF5.42M
Enterprise ValueCHF5.05M
Total Cash (Recent Filing)CHF1.64M
Total Debt (Recent Filing)CHF34.69K
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding218,654,500
10 Day Avg. Volume188,431
30 Day Avg. Volume206,072
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces insolvency and interest-rate risk, preserving financial optionality for R&D. With minimal debt the company can prioritize equity or partnership financing, maintaining flexibility to fund clinical programs and survive development cycles over the next months.
GPCR/allosteric SpecializationA focused platform in GPCR allosteric modulation is a durable technical differentiation in neurology drug discovery. Domain expertise and proprietary chemistry increase chances of valuable IP, partner interest and licensing, creating long-term leverage beyond single trials.
Partnering/licensing Funding ModelReliance on collaboration and licensing unlocks upfronts, research reimbursements, milestones and royalties that can finance development without needing commercial products. This risk-sharing model supports program advancement and reduces sole reliance on internal cash generation.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing cash burn and financing dependency. Even with 2025 improvement, continuous outflows raise dilution risk, limit capacity to run parallel trials and increase execution risk if partner funding or new financing is delayed.
Small, Volatile RevenueLow and inconsistent revenue makes budgeting and multi-year R&D planning fragile, forcing reliance on milestone timing and external financings. Volatility reduces predictability of runway and heightens vulnerability to single-event outcomes or partner timetables.
Structurally Weak ProfitabilityOperating losses and sharply swinging margins (headline profit in 2024 driven by non-operating items) indicate weak earnings quality. Structural unprofitability prolongs reliance on partners/financing and increases risk of dilution absent clear clinical or licensing successes.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was CHF0.03 and its highest was CHF0.09 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF5.42M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Jun 25, 2026 which is in 3 days.
How were Addex Therapeutics’s earnings last quarter?
Currently, no data Available
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in CH:ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Options Prices
Currently, No data available
---